Differential scanning calorimetry (DSC) of blood serum in chronic obstructive pulmonary disease (COPD)
- 155 Downloads
Chronic obstructive pulmonary disease (COPD) is a major global health challenge with a gloom perspective of being one of the big three cause of death by 2020. No reliable/reproducible biomarker has been identified so far to match the clinically-based staging system (GOLD). Blood samples of 30 subjects divided into 6 groups (no-COPD/-smoker, no-COPD/non-smoker, COPD I, COPD II, COPD III, COPD IV) with 5 patients in each were tested by differential scanning calorimetry. There is a clear 15.4 % difference between the heat flow maxima measured when no-COPD subjects were compared in accordance to their smoking/non-smoking status. Odds ratio of different heat flow in actively smoking COPD patients in stage IV and stage I was 1.61. A reverse tendency is detected in the relevant non-smoking COPD groups. The differences are inconsistent in intermediate stages (COPD II and III). DSC seems to be an applicable and objective method for monitoring nicotine abuse. There is a chance to detect specific typology of thermokinetic patterns in the two extremes of COPD (I vs. IV). Further studies with increased sample size are needed to allow calculations on specificity/sensitivity/positive and negative predictive value of enthalpies and heat flow maximums. The first clinically relevant blood-based COPD marker on the intravascular side of the alveo-capillary screen is demonstrated by our pilot study.
KeywordsDifferential scanning calorimetry (DSC) Chronic obstructive pulmonary disease (COPD) COPD severity Global initiative for chronic obstructive lung disease (GOLD)
The SETARAM Micro DSC-II was purchased with a grant (CO-272) from the Hungarian Scientific Research Fund (D. Lőrinczy).
- 1.Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverly P, Fukuchi Y, Jenkins C, Rodriquez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Resp Crit Care Med. 2007;176:532–55.CrossRefGoogle Scholar
- 7.Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users’ guides to the medical literature: XIX. Applying clinical trial results: A. How to use an article measuring the effect of an intervention on surrogate end points: Evidence-Based Medicine Working Group. JAMA. 1999;282:771–8.CrossRefGoogle Scholar
- 8.Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge P, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF, On behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–69.Google Scholar
- 14.De Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aquirre-Jaime A, Celli BR, Casanova C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27:902–7.Google Scholar
- 17.Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.Google Scholar
- 18.Wang TS, Duan SF, Tang TQ. Hemorrheologic changes in COPD patients with or without cor pulmonale. J Tongji Med Univ. 1998;8(4):235–7.Google Scholar
- 19.Coppola L, Verrazzo G, Esposito G, La Marca C, Mazzarelli R, Guastafierro S, Giunta R, Giugliano D, Varricchio M. Hemorheological and cardiovascular effects of exercise training in the rehabilitation of elderly patients with chronic obstructive pulmonary disease. Arch Gerontol Geriatr. 1999;28(1):1–8.CrossRefGoogle Scholar
- 25.Michnik A, Drzazga Z, Michalik K, Barczyk A, Santura I, Sozan′ska E, Pierzchała W. Differential scanning calorimetry study of blood serum in chronic obstructive pulmonary disease. J Therm Anal Calorim. 2010;102:57–60.Google Scholar
- 29.Read J. The lungs and circulation in chronic pulmonary disease. J R Coll Physicians Lond. 1971;5(3):221–31.Google Scholar
- 30.Schönhofer B. The optimal hematocrit and hemoglobin values in lung diseases. Wien Klin Wochenschr. 2001;113(Suppl 1):6–8.Google Scholar